Recognising the importance of early intervention, Allergan ANZ invited delegates at the 2018 RANZCO Scientific Congress to witness its agreement to give Glaucoma Australia A$300,000 over three years to help eliminate blindness from glaucoma.

“The focus for the partnership will be on early detection and treatment adherence to help prevent irreversible blindness, and boosting education and support available to existing patients,” said George Labib, Allergan ANZ’s director of medical and scientific affairs in Adelaide.

Joining him on Allergan’s stand, Annie Gibbins, CEO of Glaucoma Australia, said the partnership meant Glaucoma Australia can now confidently fund its programmes to eliminate blindness from glaucoma, so there’s definitely some “exciting times ahead”.

“The significant support Allergan is providing will increase our capacity to provide a higher level of tailored education and support to patients referred to us. Together, we aim to save sight by improving early detection and treatment adherence.”